Proliferative Vitreoretinopathy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The proliferative vitreoretinopathy market size is projected to expand from USD 82.38 million in 2025 and USD 86.94 million in 2026 to USD 113.85 million by 2031, registering a CAGR of 5.54% between 2026 to 2031. This report is Segmented by Treatment Type (Surgical Treatment, and More), Disease Stage (Grade A PVR, Grade B PVR, and Grade C PVR), Surgical Device Type (Vitrectomy Machines, Vitrectomy Probes, and More), End User (Hospitals, Specialty Eye Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Proliferative Vitreoretinopathy Market Trends and Insights

Rising Rhegmatogenous Incidence Anchors PVR Procedural Pipeline

Germany’s nationwide data showed rhegmatogenous retinal detachment incidence rising to 24.8 per 100,000 by 2021 from 15.6 per 100,000 in 2005, which confirms that the upstream case pool for complex retinal repair is still growing. The share of detachment cases that progress to PVR has remained near 5% to 10%, so absolute PVR volumes increase as detachment volumes increase, even when surgical methods improve. This matters for the proliferative vitreoretinopathy market because demand is tied to a failure pattern that has not been eliminated by surgical refinement. Myopia continues to sit upstream of this burden, which keeps future case expansion linked to long-duration refractive disease trends rather than only to acute surgical capacity. The result is a durable procedural base for the proliferative vitreoretinopathy market, especially in regions where aging and myopia are moving in the same direction. Hospitals and tertiary retina centers, therefore, continue to treat PVR as a recurring service line rather than as a shrinking surgical complication.

Advanced Vitreoretinal Platforms Reshaping Surgical Standard of Care

The current product cycle remains unusually active, with Alcon’s UNITY VCS moving through commercial rollout with the HYPERVIT 30K probe and upgraded fluidics architecture. Bausch + Lomb’s Bi-Blade+ dual-port vitrectomy cutter adds another high-specification option with 25,000 cuts per minute and a reported 62% reduction in cutter vibration, which is directly relevant in delicate membrane work. These upgrades improve control, visibility, and workflow efficiency in the operating room, but they do not remove the clinical judgment required in severe PVR surgery. That dynamic supports the proliferative vitreoretinopathy market by raising the revenue value of each procedure without removing the need for repeat intervention in difficult cases. It also sustains a device replacement cycle that benefits premium platform vendors across installed base accounts. As more facilities invest in integrated systems, the proliferative vitreoretinopathy market keeps shifting toward bundled purchases rather than stand-alone instrument decisions.

Absence of Approved Pharmacological Therapy Narrows Treatment Options

No FDA, EMA, or other major regulatory approval exists for a PVR drug in 2026, which leaves surgery as the only established route of care. A systematic review covering 27 randomized controlled trials and 3,375 patients found that commonly tested pharmacological approaches did not deliver reproducible clinical benefit in large studies. That evidence gap keeps the proliferative vitreoretinopathy market dependent on repeat mechanical intervention, including vitrectomy, silicone oil tamponade, and membrane peeling. Patient heterogeneity also complicates product development, because preoperative PVR grade remains a strong predictor of post-surgical failure and makes clean trial stratification difficult. This slows commercial entry for would-be adjunct therapies even when the unmet need is obvious. As a result, the proliferative vitreoretinopathy market carries high clinical demand but a still-unproven drug pathway.

Other drivers and restraints analyzed in the detailed report include:

• Aging Population Expands PVR-Eligible Surgical Pool
• Anti-Fibrotic Pipeline Redefining Pharmacological Adjunct Strategy
• Recurrence Dynamics Create Clinical and Economic Friction

Segment Analysis

Surgical treatment accounted for 72.43% of revenue in 2025, which made it the largest contributor to the proliferative vitreoretinopathy market size. This dominance reflects the fact that pars plana vitrectomy, membrane peeling, and tamponade remain the only interventions with established efficacy across the disease spectrum. Smaller-gauge surgery and better visualization have improved precision in the operating room, but they have not displaced the core surgical pathway. The revenue base of the proliferative vitreoretinopathy market, therefore, remains centered on procedures, devices, and recurring surgical consumables. Within the proliferative vitreoretinopathy industry, this makes the operating room the primary point of value capture.

Pharmacological and adjunctive treatment is projected to grow at 9.23% CAGR from 2026 to 2031, which makes it the fastest-growing treatment category in the user-supplied structure. That faster pace comes from trial activity and not from present-day commercial scale, which is an important distinction in this segment. Aldeyra’s ADX-2191 remains one of the clearest named assets in this space, with FDA Special Protocol Assessment support already on record for a pivotal pathway. Journal evidence also notes that PVR incidence has not materially declined despite surgical advances, which preserves the case for a pharmacological complement rather than a surgical substitute. That is why the proliferative vitreoretinopathy market can support strong attention to adjunct drugs even while surgery continues to hold the revenue lead.

Grade C captured 53.28% of the proliferative vitreoretinopathy market share in 2025, which shows how heavily real-world treatment still concentrates in advanced disease. This pattern reflects delayed referral, limited specialist access, and the fact that many patients reach tertiary care only after the first retinal repair has already failed. Grade C cases usually require the most resource-intensive mix of membrane peeling, retinotomy, and silicone oil use, which makes them commercially important but clinically difficult. The proliferative vitreoretinopathy market gains revenue from that intensity, but it also inherits weaker efficiency because late-stage care consumes more resources per patient. Within the proliferative vitreoretinopathy industry, Grade C remains the segment where clinical need and economic burden are most concentrated.

Grade A is projected to grow at 9.79% CAGR through 2031, which makes it the fastest-growing disease stage in the segment framework. That change points to a stronger interest in identifying high-risk retinal detachment patients before aggressive scarring becomes established. A 2026 review identified laser flare photometry at a threshold of at least 15 photons/ms as a useful stratification tool for selecting patients at higher risk before clinically significant PVR develops. Grade B is also becoming more important because it sits near the point where academic centers consider adjunctive methotrexate protocols and tighter post-operative monitoring. Over time, the proliferative vitreoretinopathy market is likely to depend more on earlier identification and less on a purely rescue-oriented Grade C treatment model.

Complete Report Scope:

• By Treatment Type
  • Surgical Treatment
  • Pharmacological and Adjunctive Treatment
• By Disease Stage
  • Grade A PVR
  • Grade B PVR
  • Grade C PVR
• By Surgical Device Type
  • Vitrectomy Machines
  • Vitrectomy Probes
  • Intraocular Tamponades
  • Ophthalmic Visualization Systems
  • Others
• By End User
  • Hospitals
  • Specialty Eye Hospitals
  • Ambulatory Surgery Center
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 38.64% of the proliferative vitreoretinopathy market share in 2025, which made it the largest regional contributor. The United States remains the primary revenue center because it combines a high density of retinal surgeons, established reimbursement pathways, and early adoption of premium vitreoretinal technology. Massachusetts Eye and Ear is running both netarsudil and topotecan prevention studies, which keep the region closely connected to the next wave of adjunct treatment development. Canada received Health Canada approval for Alcon’s UNITY VCS in July 2026, which extends access to current-generation vitreoretinal platform technology across the region. Mexico remains a smaller revenue source, but its contribution improves as tertiary retinal care infrastructure expands in selected hospital systems.

Europe represents the second-largest regional block in the proliferative vitreoretinopathy market, supported by Germany, the UK, France, Italy, and Spain. Germany’s adjusted rhegmatogenous retinal detachment incidence reached 24.8 per 100,000 by 2021, which creates a steady downstream pool for PVR-related surgery. The UK and France remain important through tertiary referral concentration and specialist engagement in trial design, which keeps Europe relevant beyond its installed device base. Suppliers are also benefiting from high surgeon familiarity with premium visualization and vitrectomy systems across academic and large referral centers. EU MDR compliance is raising the barrier for smaller device entrants, which favors suppliers that already have the scale and regulatory capability to stay present in hospital tenders.

Asia-Pacific is forecast to expand at 12.38% CAGR through 2031, making it the fastest-growing region in the proliferative vitreoretinopathy market. China’s 2026 approvals for ZEISS ARTEVO 750 and ARTEVO 850, together with DORC’s 2025 ILM-Blue approval, show that premium retinal technologies are moving deeper into high-volume centers. Japan and South Korea add further demand through older populations and mature retinal surgery capacity, while consensus guidance from APVRS is helping align surgical practice across member markets. Middle East and Africa and South America remain smaller opportunities in the proliferative vitreoretinopathy market, with Brazil and Argentina standing out, but growth still depends on faster referral, earlier diagnosis, and a larger retina specialist base.

List of Companies Covered in this Report:

• Abbvie
• Alcon
• Aldeyra Therapeutics
• Alimera Sciences, Inc.
• Bausch + Lomb Corporation
• BVI Medical
• Carl Zeiss
• Carl Zeiss
• DORC (Dutch Ophthalmic Research Center)
• Roche
• Genentech
• HOYA
• Johnson & Johnson
• Danaher
• Nidek
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Tetra Bio-Pharma Inc.
• Topcon

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support